| 产品名称： | Human Coxsackievirus A 24 |
|---|---|
| 商品货号： | TS213276 |
| Classification： | Picornaviridae, Enterovirus, Human enterovirus C |
| Agent： | Human Coxsackievirus A 24 |
| Strain： | DN-19 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This item is a mycoplasma free preparation derived from VR-583 following treatment to remove mycoplasma. VR-583 will no longer be distributed when current inventory is depleted. Strain DN-19 is considered to be an antigenic variant or "prime" of Human coxsackievirus A 24. It was originally known as Echovirus 34. |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This item is a mycoplasma free preparation derived from VR-583 following treatment to remove mycoplasma. VR-583 will no longer be distributed when current inventory is depleted. Strain DN-19 is considered to be an antigenic variant or "prime" of Human coxsackievirus A 24. It was originally known as Echovirus 34. |
| Effect on Host： | CPE in culture include highly refractile, rounded cells throughout monolayer or in loose clusters CPE in culture include highly refractile, rounded cells throughout monolayer or in loose clusters. |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: WI-38 (ATCC CCL-75) Recommended Host: xa0WI-38 cells (ATCC® CCL-75x99) Alternate Hosts: Human embryonic kidney cells, human aorta cells (A-39) |
| Growth Conditions： | For best results, plate cells 24-48 hours in advance. Infect at 80%-90% confluence using a multiplicity of infection (MOI) of 0.1 to 1.0. Incubate at 37.0°C in a humidified, 5% CO2 atmosphere for 2-4 days, until CPE are well advanced in 100% of the culture. Harvest cells and culture fluids; cell debris can be removed by centrifugation if desired. |
| Name of Depositor： | HA Wenner |
| Source： | Isolated from infant with diarrhea, Texas, 1963; derived from ATCC VR-583 following treatment to remove mycoplasma contamination. |
| References： | The Work of WHO Virus Reference Centers and the Services they Provide, Geneva. Bull. World Health Organ 11: 1968. Schmidt NJ, Lennette EH. Antigenic variants of coxsackievirus type A24. Am. J. Epidemiol. 91: 99-109, 1970. PubMed: 4313417 Rosen L et al. Subclassification of enteroviruses and ECHO virus type 34. Brief report. Archives of Virology 30: 89-92, 1970. PubMed: 4986680. Brown BA. Resolving ambiguities in genetic typing of human enterovirus species C clinical isolates and identification of enterovirus 96, 99 and 102. J. Gen. Virol. 90 (PT 7): 1713-1723, 2009. PubMed: 19264596 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Human Coxsackievirus A 24 |
|---|---|
| 商品货号： | TS213276 |
| Classification： | Picornaviridae, Enterovirus, Human enterovirus C |
| Agent： | Human Coxsackievirus A 24 |
| Strain： | DN-19 |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | This item is a mycoplasma free preparation derived from VR-583 following treatment to remove mycoplasma. VR-583 will no longer be distributed when current inventory is depleted. Strain DN-19 is considered to be an antigenic variant or "prime" of Human coxsackievirus A 24. It was originally known as Echovirus 34. |
| Product Format： | frozen |
| Storage Conditions： | -70°C or colder |
| Comments： | This item is a mycoplasma free preparation derived from VR-583 following treatment to remove mycoplasma. VR-583 will no longer be distributed when current inventory is depleted. Strain DN-19 is considered to be an antigenic variant or "prime" of Human coxsackievirus A 24. It was originally known as Echovirus 34. |
| Effect on Host： | CPE in culture include highly refractile, rounded cells throughout monolayer or in loose clusters CPE in culture include highly refractile, rounded cells throughout monolayer or in loose clusters. |
| Growth Medium： | ATCC® Medium 30-2003: Eagles Minimum Essential Medium (EMEM) Fetal Bovine Serum |
| Recommended Host： | Production Host: WI-38 (ATCC CCL-75) Recommended Host: xa0WI-38 cells (ATCC® CCL-75x99) Alternate Hosts: Human embryonic kidney cells, human aorta cells (A-39) |
| Growth Conditions： | For best results, plate cells 24-48 hours in advance. Infect at 80%-90% confluence using a multiplicity of infection (MOI) of 0.1 to 1.0. Incubate at 37.0°C in a humidified, 5% CO2 atmosphere for 2-4 days, until CPE are well advanced in 100% of the culture. Harvest cells and culture fluids; cell debris can be removed by centrifugation if desired. |
| Name of Depositor： | HA Wenner |
| Source： | Isolated from infant with diarrhea, Texas, 1963; derived from ATCC VR-583 following treatment to remove mycoplasma contamination. |
| References： | The Work of WHO Virus Reference Centers and the Services they Provide, Geneva. Bull. World Health Organ 11: 1968. Schmidt NJ, Lennette EH. Antigenic variants of coxsackievirus type A24. Am. J. Epidemiol. 91: 99-109, 1970. PubMed: 4313417 Rosen L et al. Subclassification of enteroviruses and ECHO virus type 34. Brief report. Archives of Virology 30: 89-92, 1970. PubMed: 4986680. Brown BA. Resolving ambiguities in genetic typing of human enterovirus species C clinical isolates and identification of enterovirus 96, 99 and 102. J. Gen. Virol. 90 (PT 7): 1713-1723, 2009. PubMed: 19264596 |
